1 week Ago By Defense World Staff
Norges Bank bought a new stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,454 shares of the biotechnology company’s stock, valued at approximately $796,000.
Norges Bank owned 0.11% of Prothena at the end of the most recent reporting period. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company.
Vanguard Group Inc. boosted its holdings in shares of Prothena by 11.5% in the 4th quarter.
Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company’s stock valued at $19,443,000 after acquiring an additional 144,737 shares during the last quarter. JPMorgan Chase & Co.
boosted its holdings in Prothena by 93.7% in the fourth quarter. JPMorgan Chase & Co.
now owns 387,350 shares of the biotechnology company’s stock valued at $5,365,000 after purchasing an additional 187,364 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Prothena by 0.
7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 327,151 shares of the biotechnology company’s stock worth $4,531,000 after purchasing an additional 2,189 shares during the period.
Bank of New York Mellon Corp raised its stake in shares of Prothena by 14.9% during the 4th quarter. Bank of New York Mellon Corp now owns 150,238 shares of the biotechnology company’s stock valued at $2,081,000 after buying an additional 19,452 shares during the last quarter.
Finally, Barclays PLC lifted its holdings in shares of Prothena by 110.2% in the 3rd quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 49,916 shares during the period.
Hedge funds and other institutional investors own 97.08% of the company’s stock. Prothena Stock Up 5.
5 %Shares of NASDAQ PRTA opened at $10.22 on Friday. The firm has a market cap of $550.
11 million, a price-to-earnings ratio of -4.44 and a beta of 0.07.
The company’s 50-day simple moving average is $13.37 and its 200-day simple moving average is $14.72.
Prothena Co. plc has a 52-week low of $9.30 and a 52-week high of $25.
42. Prothena (NASDAQ:PRTA – Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.
08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.06).
Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.
The firm had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million.
Equities research analysts anticipate that Prothena Co. plc will post -4.04 EPS for the current fiscal year.
Analyst Ratings ChangesSeveral analysts recently commented on the company. Oppenheimer raised their target price on Prothena from $58.00 to $62.
00 and gave the stock an “outperform” rating in a report on Friday, February 7th. Royal Bank of Canada cut their target price on shares of Prothena from $24.00 to $20.
00 and set a “sector perform” rating for the company in a report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Piper Sandler raised their price target on shares of Prothena from $94.
00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Chardan Capital reissued a “buy” rating and set a $40.
00 target price on shares of Prothena in a research note on Friday, February 21st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.Read Our Latest Stock Report on PRTAProthena Company Profile (Free Report)Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.Read MoreFive stocks we like better than ProthenaTrading Stocks: RSI and Why it’s UsefulRobinhood Strategies Could Be a Game-Changer for Young Investors3 Ways To Invest In Coffee, Other Than Drinking ItAre These 3 Retail Stocks Oversold or Really in Trouble?Stock Average Calculator IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
